PT866691E - Administracao sublingual e bucal de selegilina - Google Patents
Administracao sublingual e bucal de selegilinaInfo
- Publication number
- PT866691E PT866691E PT96938783T PT96938783T PT866691E PT 866691 E PT866691 E PT 866691E PT 96938783 T PT96938783 T PT 96938783T PT 96938783 T PT96938783 T PT 96938783T PT 866691 E PT866691 E PT 866691E
- Authority
- PT
- Portugal
- Prior art keywords
- selegiline
- conditions
- diseases
- sublingual
- responsive diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US732595P | 1995-11-06 | 1995-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT866691E true PT866691E (pt) | 2002-11-29 |
Family
ID=21725510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT96938783T PT866691E (pt) | 1995-11-06 | 1996-11-05 | Administracao sublingual e bucal de selegilina |
Country Status (13)
Country | Link |
---|---|
US (1) | US6117912A (pt) |
EP (1) | EP0866691B2 (pt) |
JP (1) | JPH11504944A (pt) |
CN (1) | CN1207675A (pt) |
AT (1) | ATE219358T1 (pt) |
AU (1) | AU707646B2 (pt) |
CA (1) | CA2236368C (pt) |
DE (1) | DE69621946T3 (pt) |
DK (1) | DK0866691T4 (pt) |
ES (1) | ES2180809T5 (pt) |
NO (1) | NO317855B1 (pt) |
PT (1) | PT866691E (pt) |
WO (1) | WO1997017067A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050106241A1 (en) * | 1995-02-03 | 2005-05-19 | Brewer Francesca M. | Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors |
NZ302723A (en) † | 1995-03-02 | 1998-04-27 | Scherer Ltd R P | Composition comprising monoamine oxidase b inhibitor and a carrier formulated for pre-gastric absorption of the monoamine oxidase b inhibitor |
GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6576250B1 (en) | 1998-03-27 | 2003-06-10 | Cima Labs Inc. | Pharmaceutical compositions for rectal and vaginal administration |
US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
DE19814257A1 (de) | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
US7232830B2 (en) * | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
AU2004242477B2 (en) * | 1999-03-26 | 2007-04-19 | Cima Labs Inc. | Sublingual buccal effervescent |
AU2007203233B2 (en) * | 1999-03-26 | 2010-02-25 | Cima Labs Inc. | Sublingual buccal effervescent |
GB0017952D0 (en) * | 2000-07-22 | 2000-09-13 | Univ Manchester | Treatment of dyskinesia |
US20030232890A1 (en) | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
TWI291871B (en) * | 2000-11-01 | 2008-01-01 | Cognition Pharmaceuticals Llc | Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning |
EP1743631A3 (en) * | 2000-11-01 | 2009-11-18 | Cognition Pharmaceuticals LLC | Use of an amphetamine composition for regulating memory consolidation |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
AU2003210597A1 (en) * | 2002-01-18 | 2003-07-30 | Tatton Technologies, Llc. | Methods for treating eye disorders |
US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
BRPI0418228B8 (pt) * | 2003-12-31 | 2021-05-25 | Cima Labs Inc | forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil |
AU2004311879B2 (en) * | 2003-12-31 | 2010-08-05 | Cima Labs Inc. | Effervescent oral opiate dosage form |
WO2006091544A2 (en) * | 2005-02-22 | 2006-08-31 | Northwestern University | Methods and compositions for modulating calcium channels |
WO2007005879A2 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
CN103860503A (zh) * | 2012-12-10 | 2014-06-18 | 天津市汉康医药生物技术有限公司 | 一种治疗帕金森病的缓释药物组合物及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3764144D1 (de) * | 1986-04-16 | 1990-09-13 | Asta Pharma Ag | Synergistische kombination von amantadin und selegilin. |
ATE76747T1 (de) * | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
US4885154A (en) * | 1988-03-01 | 1989-12-05 | Alza Corporation | Method for reducing sensitization or irritation in transdermal drug delivery and means therefor |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
HU208484B (en) * | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
CA2039194C (en) * | 1990-08-31 | 1997-01-28 | Norton W. Milgram | Uses of l-deprenyl and compositions for same |
US5151449A (en) * | 1990-08-31 | 1992-09-29 | Deprenyl Animal Health, Inc. | Use of L-deprenyl for retention of specific physiological functions |
US5192808A (en) * | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5444095A (en) * | 1991-04-04 | 1995-08-22 | University Of Toronto, Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
US5266332A (en) * | 1991-12-06 | 1993-11-30 | Alza Corporation | Method for administering anti-Parkinson drug |
US5242950A (en) * | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
NZ302723A (en) * | 1995-03-02 | 1998-04-27 | Scherer Ltd R P | Composition comprising monoamine oxidase b inhibitor and a carrier formulated for pre-gastric absorption of the monoamine oxidase b inhibitor |
-
1996
- 1996-11-05 DK DK96938783T patent/DK0866691T4/da active
- 1996-11-05 DE DE69621946T patent/DE69621946T3/de not_active Expired - Fee Related
- 1996-11-05 CA CA002236368A patent/CA2236368C/en not_active Expired - Fee Related
- 1996-11-05 AT AT96938783T patent/ATE219358T1/de not_active IP Right Cessation
- 1996-11-05 JP JP9518280A patent/JPH11504944A/ja active Pending
- 1996-11-05 AU AU76080/96A patent/AU707646B2/en not_active Ceased
- 1996-11-05 WO PCT/US1996/017745 patent/WO1997017067A1/en active IP Right Grant
- 1996-11-05 CN CN96199433A patent/CN1207675A/zh active Pending
- 1996-11-05 PT PT96938783T patent/PT866691E/pt unknown
- 1996-11-05 ES ES96938783T patent/ES2180809T5/es not_active Expired - Lifetime
- 1996-11-05 EP EP96938783A patent/EP0866691B2/en not_active Expired - Lifetime
-
1998
- 1998-04-28 US US09/066,916 patent/US6117912A/en not_active Expired - Fee Related
- 1998-05-05 NO NO19982044A patent/NO317855B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69621946T2 (de) | 2003-01-30 |
EP0866691B1 (en) | 2002-06-19 |
DE69621946T3 (de) | 2005-05-25 |
ES2180809T5 (es) | 2005-06-16 |
CN1207675A (zh) | 1999-02-10 |
NO982044D0 (no) | 1998-05-05 |
NO982044L (no) | 1998-07-02 |
WO1997017067A1 (en) | 1997-05-15 |
DE69621946D1 (de) | 2002-07-25 |
ES2180809T3 (es) | 2003-02-16 |
DK0866691T3 (da) | 2002-10-14 |
CA2236368C (en) | 2001-10-23 |
DK0866691T4 (da) | 2005-06-06 |
AU707646B2 (en) | 1999-07-15 |
AU7608096A (en) | 1997-05-29 |
EP0866691A1 (en) | 1998-09-30 |
CA2236368A1 (en) | 1997-05-15 |
JPH11504944A (ja) | 1999-05-11 |
ATE219358T1 (de) | 2002-07-15 |
EP0866691B2 (en) | 2005-01-26 |
US6117912A (en) | 2000-09-12 |
NO317855B1 (no) | 2004-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT866691E (pt) | Administracao sublingual e bucal de selegilina | |
SE9503924D0 (sv) | Novel opioid peptides | |
LU91181I2 (fr) | Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt). | |
WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
HUP0105027A2 (hu) | N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk | |
PL361341A1 (en) | Novel pharmaceutical composition | |
DE69006072T2 (de) | Verfahren zur Herstellung von N-Methyl-3-(p-Trifluoromethyl-phenoxy)-3-phenyl-propylamin und ihre Salze. | |
ATE206916T1 (de) | Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen | |
KR0148213B1 (en) | Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same | |
HUP0003174A2 (hu) | 20(S)-Kamptotecin glikokonjugátumai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
MX9707642A (es) | Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos. | |
TR200000455T2 (tr) | Alzheimer hastalığının tedavisinde fankinonun kullanılması. | |
BR9506956A (pt) | Composição farmacêutica antitussígena | |
KR980000445A (ko) | 인식 증강 방법 | |
HUP9902415A2 (hu) | Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására | |
CO4910113A1 (es) | Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion | |
CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
ATE371737T1 (de) | Proteaseresistente flint-analoge | |
DE69729201T2 (de) | Sulfonfluoride zur behandlung von der alzheimerischen krankheit | |
EP0383481A3 (en) | Anesthetic oral compositions | |
MX9303074A (es) | Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer. | |
MY132436A (en) | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases | |
HUP0004647A2 (hu) | Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE201993T1 (de) | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie | |
EA199800941A1 (ru) | Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона |